(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
Equillium's earnings in 2026 is -$24,417,000.On average, 4 Wall Street analysts forecast EQ's earnings for 2026 to be -$15,052,820, with the lowest EQ earnings forecast at -$14,322,100, and the highest EQ earnings forecast at -$15,345,107. On average, 4 Wall Street analysts forecast EQ's earnings for 2027 to be -$13,798,418, with the lowest EQ earnings forecast at -$13,128,592, and the highest EQ earnings forecast at -$14,066,348.
In 2028, EQ is forecast to generate -$26,969,635 in earnings, with the lowest earnings forecast at -$25,660,429 and the highest earnings forecast at -$27,493,317.